Compensation 990
OrganizationsEmployeesBoard MembersGrantsContractorsTop RankingsPricing

Stay updated on 990 organization compensation

© Civic Register LLC

Compensation 990 is an independent service that uses public IRS Form 990 filings as its source data. We clean and standardize this information, but the original filings may contain errors or omissions. Years on this site refer to the organization’s fiscal year end date on the filing.

About•Report a discrepancy•Your privacy choices
Organizations Medical Research Foundation for Angelman Syndrome Therapeutics

Foundation for Angelman Syndrome Therapeutics

Fiscal year ending 2022. Filed on November 16, 2023.

PO Box 40307
300
Austin, Texas 78704

Foundation for Angelman Syndrome Therapeutics (EIN: 26-3160079) has filed an IRS Form 990 since at least fiscal year 2016. In its fiscal year 2022 IRS Form 990 filing, Foundation for Angelman Syndrome Therapeutics, a 501(c)(3) charitable organization, reported compensation for 4 out of 8 total employees. Among the employees shown here, the average compensation is $147,844. The highest compensated employee at Foundation for Angelman Syndrome Therapeutics is Kena Richert with fiscal year 2022 compensation of $188,000.

Revenue, expenses, and employee compensation

Revenue

$52,477,819

Expenses

$8,933,021

Employee compensation

$929,640
Revenue, expenses, and employee compensation over time

Reported Compensated Employees

Kena Richert
Chief Financial Officer
$188,000
$188,000 No related compNo other comp
Paula Evans
Director and Former Officer
$176,687
$0 $176,687 No other comp
Allyson Berent
Chief Science Officer
$176,687
$0 $176,687 No other comp
Alana Newhouse
President and Chief Executive Officer
$50,000
$50,000 No related compNo other comp

Benchmark Employee Compensation

Non-Employee Board Members

Amelia Beatty
Secretary
Ben O'Connor
Director
John Schuellter
Chair
Kelly David
Co-Vice Chair
Kristy Dixon
Co-Vice Chairperson and Treasurer
Lauren Hoffer
Director
Megan Cross
Chief Information Officer
Nora Xu
Director
Roy Azout
Director
Ryan Jacob
Director

Contractors

AS2 Biotherapeutics LLC
Consulting
$246,108
Medicus Economics LLC
Develop a Payer and Reimbursement Strate
$174,740

Mission Statement

ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.

Revisions to this organization profile

September 30, 2025:
2024 Foundation for Angelman Syndrome Therapeutics 990 filed
November 16, 2024:
2023 Foundation for Angelman Syndrome Therapeutics 990 filed
November 16, 2023:
2022 Foundation for Angelman Syndrome Therapeutics 990 filed

Get an email when new compensation information is released for Foundation for Angelman Syndrome Therapeutics

Be the first to know when new IRS Form 990 data is published for this organization.

Related Jobs

View more jobs
Powered by Talroo
Report a discrepancy →